Armata Pharmaceuticals, Inc.（ARMP）财务数据ARMPArmata Pharmaceuticals, Inc.

Evaluating the bottom line, Armata Pharmaceuticals, Inc. maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -410.84%, while the net margin is 2953.82%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively ARMP converts its operational activities into shareholder value.

In the context of the broader market, ARMP competes directly with industry leaders such as VRXA and NKTX. With a market capitalization of $169.55M, it holds a significant position in the sector. When comparing efficiency, ARMP's gross margin of 100.00% stands against VRXA's N/A and NKTX's N/A. Such benchmarking helps identify whether Armata Pharmaceuticals, Inc. is trading at a premium or discount relative to its financial performance.

Armata Pharmaceuticals reported a gross margin of 100% across recent quarters, indicating strong profitability on sales. However, the company has faced substantial net income losses, with the latest reported at -115,346,000 USD for Q1 2026, raising concerns about its financial stability.